Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

Journal of Viral Hepatitis

Volumn 24, Issue 4, 2017, Pages 304-311

  Alonso, S ^a   Riveiro Barciela, M ^b,c   Fernandez, I ^d   Rincon D ^c,e   Real, Y ^f   Llerena, S ^g   Gea, F ^h   Olveira, A ^c,i   Fernandez Carrillo, C ^c,j   Polo, B ^k   Carrion J A ^l   Gomez A ^m   Devesa, M J ⁿ   Baliellas, C ^o   Castro, A ^p   Ampuero, J ^c,q   Granados, R ^r   Pascasio, J M ^c,s   Rubin A ^t   Salmeron, J ^u   Badia, E ^v   Planas, J M M ^w   Lens, S ^c,x   Turnes, J ^y   Montero, J L ^z   Buti, M ^b,c   Esteban, R ^b,c   Fernandez Rodriguez C M ^a   more..

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^l UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^m HOSPITAL DONOSTIA   (Spain)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^p UNIVERSITY OF A CORUÑA   (Spain)

^q HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^r HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^s HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^t HOSPITAL UNIVERSITARIO LA FE   (Spain)

^u Urology Unit   (Spain)

^v HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^w H Albacete   (Spain)

^x HOSPITAL CLÍNIC   (Spain)

^y Instituto de Investigación Sanitaria Galicia Sur   (Spain)

^z HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

more..

Author keywords

cirrhosis; daclatasvir; genotype 3; hepatitis C; ledipasvir; observational study; real world cohort; sofosbuvir; SVR12

Indexed keywords

DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; AGED; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 85006801827     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12648     Document Type: Article

References (20)

1. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666.
2. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18:e516–e522.
3. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta-analysis. J Viral Hepat. 2011;18:745–759.
4. Sofia MJ, Bao D, Chang W, et al. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53:7202–7218.
5. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100.
6. Harvoni (ledipasvir and sofosbuvir) [summary of product characteristics]. Cambridge, UK: Gilead Sciences International Ltd, 2014.
7. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13–18.
8. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.
9. Leroy V, Angus P, Bronowicki J, et al. Daclatasvir, Sofosbuvir, and Ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016;63:1430–1441.
10. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149:1454–1461 e1.
11. Hezode C, De Ledinghen V, Fontaine E, et al. Dacltasvir plus Sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. Hepatology. 2015;62:314A.
12. Foster GR, McLauchlan J, Irving W, et al. Treatment od decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol. 2015;62:S190.
13. Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008;27:1261–1268.
14. Lemoine M, Katsahian S, Ziol M, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther. 2008;28:1102–1110.
15. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–706.
16. AASLD/IDSA/IAS-USA guidelines. 2016; www.hcvguidelines.org. Accessed 24 Feb, 2016.
17. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
18. Welzel TM, Herzer K, Ferenci P, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. J Hepatol. 2015;62:S619.
19. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
20. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.